Wells Fargo & Company Begins Coverage on Heartflow (NASDAQ:HTFL)

Equities research analysts at Wells Fargo & Company began coverage on shares of Heartflow (NASDAQ:HTFL) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $38.00 price target on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 23.30% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Stifel Nicolaus boosted their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Canaccord Genuity Group raised their target price on shares of Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Stock Down 0.9%

Shares of NASDAQ:HTFL opened at $30.82 on Wednesday. The firm has a market capitalization of $2.62 billion and a PE ratio of -17.03. The business has a 50-day moving average of $30.73. Heartflow has a fifty-two week low of $25.38 and a fifty-two week high of $41.22.

Insider Buying and Selling

In related news, Director Jeffrey C. Lightcap purchased 40,000 shares of Heartflow stock in a transaction on Tuesday, December 16th. The stock was purchased at an average cost of $26.34 per share, with a total value of $1,053,600.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $1,053,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. TFC Financial Management Inc. bought a new stake in shares of Heartflow in the third quarter valued at about $40,000. Emerald Mutual Fund Advisers Trust bought a new position in Heartflow during the third quarter valued at about $4,418,000. TrueMark Investments LLC acquired a new position in Heartflow in the 3rd quarter valued at approximately $918,000. Baillie Gifford & Co. bought a new stake in shares of Heartflow in the 3rd quarter worth approximately $101,182,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Heartflow during the 3rd quarter worth approximately $234,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.